Pharma Business – October 19, 2026
Danish Ascendis Pharma has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP), recommending EU approval of once-weekly TransCon CNP (navepegritide) for children with achondroplasia.
Clinical Trials – October 19, 2026
BioInvent has published results from the first clinical study of its anti-TNFR2 antibody BI-1808 in Clinical Cancer Research. In the Phase 1 dose escalation, no maximum tolerated dose was reached and all treatment-related side effects were grade 1 or 2.
Pharma article – October 19, 2026
Norwegian microbiome diagnostics company Genetic Analysis is presenting results today at UEG Week 2026 in Barcelona on GA-map IBD Precision Dx, a test designed to identify, at diagnosis, which ulcerative colitis patients are at risk of an aggressive disease course.
Clinical Trials – October 19, 2026
Calluna Pharma has completed dosing in its Phase 2 AURORA study of CAL101 in idiopathic pulmonary fibrosis (IPF). Topline results are expected in the first quarter of 2027.
Profiles in Business – October 18, 2026
Sesselja Ómarsdóttir has spent her career moving between academia and industry, from lichen chemistry in an Icelandic lab to leading Genis today. She talks about mentorship, curiosity, and what it means to keep one foot in each world.
Pharma Business – October 16, 2026
Stockholm-based Sobi has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP), recommending an expanded indication for Tryngolza (olezarsen) to treat adults with severe hypertriglyceridemia (sHTG).
Clinical Trials – October 19, 2026
Danish Evaxion reports that all patients in its Phase 2 trial of the personalized cancer vaccine EVX-01 in advanced melanoma kept their clinical responses at the three-year follow-up, with no tumor progression observed.
Clinical Trials – October 19, 2026
BioInvent has published results from the first clinical study of its anti-TNFR2 antibody BI-1808 in Clinical Cancer Research. In the Phase 1 dose escalation, no maximum tolerated dose was reached and all treatment-related side effects were grade 1 or 2.
Clinical Trials – October 19, 2026
Calluna Pharma has completed dosing in its Phase 2 AURORA study of CAL101 in idiopathic pulmonary fibrosis (IPF). Topline results are expected in the first quarter of 2027.
Clinical Trials – October 15, 2026
Modus Therapeutics has temporarily paused enrollment in Part 2 of its Phase IIa study of sevuparin in chronic kidney disease (CKD) with anemia after a serious adverse event in one patient. The company’s preliminary assessment is that the proof-of-concept readout will slip to the first quarter of 2027.
Clinical Trials – October 14, 2026
Swedish biosimilar developer Xbrane Biopharma has fully recruited the pivotal clinical trial of Xdivane, its biosimilar candidate to Bristol Myers Squibb’s cancer immunotherapy Opdivo (nivolumab).
Clinical Trials – October 12, 2026
Eight out of twelve patients with B-cell lymphoma and no remaining curative treatment options achieved a complete metabolic response after treatment with Elicera Therapeutics’ ELC-301. The results come from the now-completed Phase I part of the Swedish CARMA study.
Confidential
PharmaRelations is recruiting a Medical Device Auditor, on behalf of an innovative and fast-growing organization operating at the intersection of medical technology, regulatory compliance, and advanced digital solutions.
Karl Storz Endoskop Sverige AB
KARL STORZ är ett tyskt medicintekniskt företag som specialiserar sig på tillverkning och försäljning av endoskopisk utrustning och kirurgiska instrument. Företaget grundades 1945 i Tuttlingen av Dr. Karl Storz och har en lång historia av innovation inom medicinsk teknik.
PharmaRelations
You will have the opportunity to work in a team of PV specialists, helping our clients with the best solutions depending on their needs.
Micrel Medical Device
On behalf of Micrel Medical Devices, we are looking for an ambitious and commercially driven Area Sales Manager to develop and grow the Danish market in a newly established position.
PharmaRelations
Lead strategy, consulting and business growth across the Nordic Life Science market.
In a new job – October 13, 2026
Eric Honroth is stepping down as President Life Science and member of the Executive Team at Swedish medtech company Getinge to take on an external role.
In a new job – October 9, 2026
Rolf Sass Sørensen succeeds co-founder Martin Rose. Founders Martin Rose and Jesper Breum move on to pursue new biotech ventures while remaining shareholders in the company.
In a new job – October 9, 2026
Mendus has appointed Hans Preusting Chief Operating Officer and member of the management team, effective October 5, 2026. As a result, he steps down from the company’s board, where he has served as an independent director since May 2021.
Career choice – September 14, 2026
From Stanford’s sunlit engineering quad to SciLifeLab’s brisk knowledge hub in Stockholm, Emma Lundberg works across two distinct innovation cultures. She sees lessons for Sweden in Silicon Valley’s close links between academia, investors, and industry, but also strengths at home that should not be lost.
Careers article – August 14, 2026
Returning to work after a long, relaxing vacation can be challenging. Here are some tips to make the transition easier and less stressful.
Careers article – July 19, 2026
Thomas Karikari’s career has taken him across three continents: from Ghana to the UK and Sweden, and then to the US. Now an Associate Professor at the University of Pittsburgh and one of Nature Index’s “rising stars in ageing research”, he is helping move Alzheimer’s blood biomarkers beyond individual markers and towards a more complete picture of disease biology.
Profiles in Business – October 12, 2026
Finnish Heidi Haikala has a foot in two life science worlds. As a cancer researcher she has established her own research group at the University of Helsinki and Tampere University, and she is also a co-founder of the startup company Solid IO.
Profiles in Business – October 4, 2026
Unbeknownst to her, Jessica Martinsson’s long and varied career in research and life sciences was preparing her for her newest and possibly most influential role.
Profiles in Business – September 30, 2026
Trine Bartholdy has spent her career at the intersection of science and finance, helping early discoveries grow into companies capable of shaping the future of health. Now, as AI and global competition are reshaping the conditions for European life sciences, she and her colleagues at the BioInnovation Institute (BII) leverage decades of expertise to usher young Nordic companies toward entrepreneurial success.
Collaboration – October 16, 2026
Finnish NADMED, a University of Helsinki spin-out, has partnered with US specialty laboratory Doctor’s Data to make its NAD biomarker measurement available to healthcare practitioners across the United States.
Collaboration – October 16, 2026
AstraZeneca has signed a drug discovery collaboration and licensing agreement with the AI therapeutics company insitro. The deal, worth up to approximately USD 1.5 billion, aims to identify new drug targets and therapies for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies.
Agreement – October 14, 2026
Zealand Pharma has entered a collaboration and license agreement with Generate Biomedicines to develop AI-engineered multispecific protein therapeutics for obesity and other metabolic diseases. Generate is eligible for nearly USD 1.2 billion in milestones for the first two programs.
MedTech Business – October 15, 2026
UK digital pathology provider Diagnexia has signed an agreement to use Swedish medical imaging IT company Sectra’s cloud-based Image Exchange Portal to receive, send and report on pathology cases from NHS organizations.
MedTech Business – October 14, 2026
SciBase has secured its first positive US medical policy from a major Blue Cross Blue Shield organization: Highmark will cover the company’s Nevisense skin lesion assessment for patients being evaluated for possible melanoma.
MedTech Business – October 14, 2026
Swedish medtech company NanoEcho has been declared bankrupt after failing to find a solution to its strained financial situation.
Biotech Business – October 14, 2026
Alvotech and its partner Advanz Pharma have submitted a European regulatory application for AVT29, a proposed biosimilar to the high-dose retinal disease drug Eylea 8 mg. According to the companies, it is the first known submission of its kind worldwide.
Biotech article – October 13, 2026
The Drug Discovery and Development (DDD) platform at SciLifeLab has completed the first GMP-compatible cell line developed within BRIDGE Sweden, a national initiative to strengthen Sweden’s capacity for biologics development. The top-performing clones produce more than seven grams of monoclonal antibody per liter.
Biotech Business – October 12, 2026
Health Canada has approved Camurus’s Oczyesa XR, a once-monthly subcutaneous octreotide depot, for maintenance treatment of adults with acromegaly who have responded to and tolerated treatment with somatostatin analogs.
Science News – October 14, 2026
Women vaccinated against HPV before their first pregnancy were less likely to give birth prematurely, according to a Swedish register study from Karolinska Institutet published in The BMJ.
Funding – October 13, 2026
The Knut and Alice Wallenberg Foundation is granting SEK 900 million to thirty research projects that international experts have judged to be groundbreaking and at the forefront of global research. Ten of the projects are in medicine, spanning cancer, immunology, hearing restoration, and fibromyalgia.
Science News – October 13, 2026
Joakim Lundeberg, Professor of Molecular Biotechnology at KTH Royal Institute of Technology, has received the 2026 Gold Medal from the Royal Swedish Academy of Engineering Sciences (IVA) for developing spatial transcriptomics, a method now used in life science research worldwide.
This site uses cookies
